Clinical Trial Update: Post-marketing Safety Study of Autoimmune Diseases Following Cervarix® Vaccination

View source ↗

Summary

This post-marketing safety study evaluated potential autoimmune diseases following Cervarix vaccination; the study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cervical Cancer
• Cervical Intraepithelial Neoplasia
• Human Papillomavirus Infection

Drugs mentioned

• Cervarix (human papillomavirus vaccine, bivalent)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Infections, Papillomavirus | Status: COMPLETED